BioCentury
ARTICLE | Clinical News

Bafetinib: Phase II started

September 20, 2010 7:00 AM UTC

CytRx began the open-label, international Phase II PROACT trial to evaluate oral bafetinib given twice daily in about 50 metastatic HRPC patients who failed first-line chemotherapy. CytRx has rights t...